News and Announcements
Series 1 units of the Warburton Global Fund returned +0.3% in February 2019
- Published March 11, 2019 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Series 1 units of the Warburton Global Fund returned +0.3% in February 2019. The value of $1 invested since inception is $1.48.
The global financial markets experienced a mildly positive month. Equities were higher in most major jurisdictions. Sovereign bonds lost value in North America
and Europe but gained in value in Asia and Australia. The 2-year to 10-year section of the US yield curve steepened slightly. Commodity prices were higher for energy and industrial metals but lower for precious metals. The AUD was weaker versus the USD.
The Warburton Global Fund’s gains came from our currency, commodity and cash positions. Losses on our bond positions tempered the month’s profit.
About Warburton Investment Management
Warburton Investment Management manages client capital via the Warburton Global Fund, a global macro hedge fund that deals in international investments. The fund invests in public equity, fixed income, currency and commodity markets worldwide.
Founded in 2015, Warburton Investment Management is one of the best performing firms in the hedge fund industry, with a mandate to target annualised returns of over 30%.
Company Updates
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Backed By Leading Investment Groups and Family Offices
